Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
January 25, 2018
RegMed Investors’ (RMi) closing bell; gains improve
January 25, 2018
RegMed Investors’ (RMi) pre-open: volatility is unpredictable
January 24, 2018
RegMed Investors’ (RMi) closing bell; right again…
January 24, 2018
RegMed Investors’ (RMi) pre-open: sentiment is an attitude which allows momentum to be measurable
January 17, 2018
RegMed Investors’ (RMi) closing bell; selling the rips until the mid-day recognized the oversold and closed barely positive
January 17, 2018
RegMed Investors’ (RMi) pre-open: Celgene’s (CELG) expresses its interest in Juno Therapeutics (JUNO)
January 16, 2018
RegMed Investors’ (RMi) closing bell; the roller coaster was taking tickets
January 16, 2018
Capricor (CAPR) Licenses additional patent applications from Cedars-Sinai Medical Center (CSMC) for cellular and exosome-based technologies
January 16, 2018
RegMed Investors’ (RMi) pre-open: the indexes and ETFs tease the sector, follow us
January 12, 2018
RegMed Investors’ (RMi) closing bell; rebound followed by a relapse
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.